NuPathe to Present at Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18th.
CONSHOHOCKEN, Pa. -- NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that Jane Hollingsworth, chief executive officer, will present at the Cowen and Company 29th Annual Health Care Conference. The conference will be held at The Boston Marriott Copley Place in Boston from March 16-19, 2009. Ms. Hollingsworth will present on Wednesday, March 18, 2009, at 10:00 a.m. in the MIT Room, 3rd Floor.
Ms. Hollingsworth will provide an overview of the company and NuPathe's innovative therapeutic products, including Zelrix[TM], a transdermal patch for the treatment of acute migraine. Following the presentation, Ms. Hollingsworth and Keith Goldan, vice president and chief financial officer, will be available for questions from the audience.
Migraine affects approximately 28 million Americans, many of whom commonly experience nausea and vomiting as symptoms of the condition. For nearly three out of ten migraine sufferers, migraine-related nausea interferes with their ability to take oral medications. Zelrix combines NuPathe's SmartRelief[TM] proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine, to bypass gastrointestinal issues associated with migraine.
NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe's mission is to identify and address the needs of patients that are insufficiently met by current treatments. NuPathe's product portfolio includes Zelrix which, if approved, would be the first and only transdermal patch for the treatment of acute migraine, and NP201, a long acting injectable implant for the treatment of Parkinson's disease. Please visit NuPathe's web site at www.nupathe.com.
Zelrix is a novel transdermal patch in phase III clinical development for acute migraine. Today, only 50 percent of migraine patients are satisfied with their migraine treatment due to issues such as migraine-related nausea/vomiting, inconsistent relief, and side-effects. Zelrix was conceived and designed to address these issues and provide patients with improved ability to take control over their migraine.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Conference news|
|Date:||Mar 11, 2009|
|Previous Article:||Epic Records Proudly Announces MONUMENTS AND MELODIES - a Two Disc Greatest Hits Album from Multi-Platinum Artist Incubus.|
|Next Article:||Acacia Subsidiary Licenses Medical Picture Archiving and Communication System (PACS) Technology to McKesson.|